Abstract
Venous thromboembolism (VTE) is a leading cause of cardiovascular death. The optimal duration of anticoagulant therapy for a first unprovoked VTE is uncertain. Deciding whether to continue anticoagulation indefinitely after completing at least 3 months of initial treatment, requires balancing the long-term risk of recurrent VTE if anticoagulation is discontinued with the long-term risk of major bleeding if anticoagulation is continued. We previously showed that men with a first unprovoked VTE have a higher long-term risk of recurrent VTE than women (Khan F et al., BMJ 2019).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
